Relmada Therapeutics Inc (NASDAQ: RLMD)’s stock price has gone decline by -7.87 in comparison to its previous close of 0.77, however, the company has experienced a -13.88% decrease in its stock price over the last five trading days. seekingalpha.com reported 2025-05-12 that Relmada Therapeutics, Inc. (NASDAQ:RLMD ) Q1 2025 Earnings Call May 12, 2025 4:30 PM ET Company Participants Brian Ritchie – Investor Relations Sergio Traversa – Chief Executive Officer Maged Shenouda – Chief Financial Officer Yair Lotan – Chief, Urology and Oncology Conference Call Participants Uy Ear – Mizuho Securities Matt Barcus – Jefferies Operator Good afternoon. Welcome to the Relmada Therapeutics First Quarter 2025 Earnings Call.
Is It Worth Investing in Relmada Therapeutics Inc (NASDAQ: RLMD) Right Now?
RLMD has 36-month beta value of 0.66. Analysts have mixed views on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 3 as “hold,” and 0 as “sell.”
The public float for RLMD is 26.73M, and currently, short sellers hold a 4.22% ratio of that float. The average trading volume of RLMD on June 13, 2025 was 1.77M shares.
RLMD’s Market Performance
RLMD stock saw an increase of -13.88% in the past week, with a monthly gain of 81.08% and a quarterly increase of 159.82%. The volatility ratio for the week is 3.00%, and the volatility levels for the last 30 days are 8.10% for Relmada Therapeutics Inc (RLMD). The simple moving average for the past 20 days is 4.60% for RLMD’s stock, with a -48.92% simple moving average for the past 200 days.
Analysts’ Opinion of RLMD
Many brokerage firms have already submitted their reports for RLMD stocks, with Mizuho repeating the rating for RLMD by listing it as a “Neutral.” The predicted price for RLMD in the upcoming period, according to Mizuho is $1 based on the research report published on December 05, 2024 of the previous year 2024.
Jefferies, on the other hand, stated in their research note that they expect to see RLMD reach a price target of $13, previously predicting the price at $3.50. The rating they have provided for RLMD stocks is “Buy” according to the report published on September 17th, 2024.
Goldman gave a rating of “Sell” to RLMD, setting the target price at $2 in the report published on June 05th of the previous year.
RLMD Trading at 44.51% from the 50-Day Moving Average
After a stumble in the market that brought RLMD to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -84.20% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at RLMD starting from Kelly Paul Edward, who purchase 200,000 shares at the price of $0.43 back on May 16 ’25. After this action, Kelly Paul Edward now owns 412,295 shares of Relmada Therapeutics Inc, valued at $86,060 using the latest closing price.
Shenouda Maged, the Chief Financial Officer of Relmada Therapeutics Inc, purchase 90,000 shares at $0.49 during a trade that took place back on May 19 ’25, which means that Shenouda Maged is holding 228,335 shares at $43,686 based on the most recent closing price.
Stock Fundamentals for RLMD
The total capital return value is set at -3.52. Equity return is now at value -160.26, with -135.09 for asset returns.
Currently, EBITDA for the company is -79.98 million with net debt to EBITDA at 0.01. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.29.
Conclusion
To put it simply, Relmada Therapeutics Inc (RLMD) has had a mixed performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
